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MicroRNAs (miRNAs) are small noncoding
regulatory RNAs that reduce stability and/or
translation of fully or partially sequence-
complementary target mRNAs. In order to iden-
tify miRNAs and to assess their expressionpatterns, we sequenced over 250 small RNA
libraries from 26 different organ systems and
cell types of human and rodents that were en-
riched in neuronal as well as normal and malig-
nant hematopoietic cells and tissues. We pres-
ent expression profiles derived from clone
count data and provide computational toolsCell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc. 1401
for their analysis. Unexpectedly, a relatively
small set of miRNAs, many of which are ubi-
quitously expressed, account for most of
the differences in miRNA profiles between cell
lineages and tissues. This broad survey also
provides detailed and accurate information
about mature sequences, precursors, genome
locations, maturation processes, inferred tran-
scriptional units, and conservation patterns.
We also propose a subclassification scheme
for miRNAs for assisting future experimental
and computational functional analyses.
INTRODUCTION
MicroRNAs (miRNAs) are small (22 nucleotides) noncod-
ing regulatory RNA molecules encoded by plants,
animals, and some viruses (reviewed in Bartel, 2004;
Berezikov and Plasterk, 2005; Cullen, 2006; Mallory and
Vaucheret, 2006). They were first discovered in Caeno-
rhabditis elegans and were shown to regulate expression
of partially complementary mRNAs (Lee et al., 1993;
Wightman et al., 1993; Moss et al., 1997). Most miRNAs
are evolutionarily conserved in related species and some
even show conservation between invertebrates and verte-
brates (Pasquinelli et al., 2000; Lagos-Quintana et al.,
2001; Lau et al., 2001; Lee and Ambros, 2001). Many
miRNAs have well-defined developmental and cell-type-
specific expression patterns (reviewed in Wienholds and
Plasterk, 2005). However, for most mammalian miRNAs
the relative abundance and specificity of expression
remain to be investigated.
miRNAs regulate a variety of developmental and physi-
ological processes (reviewed in Cao et al., 2006; Plasterk,
2006; Shivdasani, 2006). The analysis of miRNA function
in animals is either performed genetically or by delivery
of synthetic miRNA precursors or antisense oligonucleo-
tides (antagomirs; reviewed recently in Kru¨tzfeldt et al.,
2006). Such analysis revealed that 100 to 200 target
mRNAs are repressed and destabilized by a single miRNA
(Kru¨tzfeldt et al., 2005; Lim et al., 2005; Linsley et al.,
2007). Other mRNAs appear to be under selective pres-
sure to avoid complementarity to coexpressed highly
abundant miRNAs (Farh et al., 2005; Stark et al., 2005;
Sood et al., 2006). Many computational studies have
been conducted to define miRNA regulatory networks
(reviewed in Rajewsky, 2006), yet most molecular targets
of miRNAs remain experimentally undefined.
Posttranscriptional editing of some double-stranded
precursor miRNAs by adenosine deamination (Luciano
et al., 2004; Pfeffer et al., 2005; Blow et al., 2006; Kawa-
hara et al., 2007) can further control targeting specificity
as well as modulate the stability and processing of miRNA
precursor transcripts (Gottwein et al., 2006; Yang et al.,
2006). Polymorphic sequence variation identified in
some other pre-miRNA sequences, in contrast, had no1402 Cell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc.effect on miRNA processing (Iwai and Naraba, 2005;
Diederichs and Haber, 2006). Regulated processing of
miRNA precursor transcripts has also been reported in
the context of cell-type and stage-specific expression
(Obernosterer et al., 2006; Thomson et al., 2006).
The increasing number of studies addressing the role of
miRNAs in development and in various diseases including
cancer emphasizes the need for a comprehensive catalog
of accurate sequence, expression, and conservation
information for the large number of recently proposed
miRNAs. Here we present a database and analysis of
over 250 small RNA cDNA libraries obtained by cloning
and sequencing. We have developed interactive analysis
tools and illustrate their utility in discovering miRNA ex-
pression changes associated with hematopoietic and ner-
vous system differentiation and malignant transformation.
RESULTS
miRNA Profiling by Sequence Analysis of Small RNA
Clone Libraries
We cloned and sequenced more than 330,000 indepen-
dent small RNA sequences from 256 small RNA libraries
prepared from 26 distinct organ systems and cell types
of human and/or rodents (Table S1) and also reanalyzed
some previously described small RNA libraries (Lagos-
Quintana et al., 2002, 2003; Poy et al., 2004). Each library
was covered by about 1,300 clones and contained on
average 65% miRNA sequences representing 70 to 75
distinct mature miRNAs (Tables S2–S4). Our small RNA
annotation procedure and miRNA profile analysis
(Figure S1) kept track of small RNA clones that mapped
equally well to more than one miRNA precursor (Tables
S5–S8). About one-third of all miRNA clones mapped to
multicopy miRNA genes with indistinguishable mature
sequences, while another 1% mapped to two or more
paralogs with related, but not identical, mature miRNA
sequences. Clone counts of miRNAs were collected in
two distinct table formats either distributing the clones
between miRNA genes or precursors (Tables S9–S11) or
collecting them as unique mature sequences (Tables
S12–S14). In the annotation process, we identified 33
new miRNAs (Table 1), and we confirmed the expression
of many evolutionarily conserved miRNAs previously only
cloned in other species.
We provide evidence for expression of 340, 303, and 205
distinct mature miRNAs from human, mouse, and rat;
these are encoded by 395, 363, and 231 different miRNA
genes, respectively. When including orthology rela-
tionships for cloned miRNAs (Table S15), we obtained
a final list of 416, 386, and 325 miRNA genes present
in human, mouse, and rat contained in 214, 190, and 168
transcription units, respectively. The 8.2 release of
miRBase includes 84, 7, and 13 additional miRNA gene
candidates for human, mouse, and rat, respectively, for
which we have not found supporting evidence in this study.
About 80% of these miRNA candidates were initially iden-
tified at very low or single clone counts in single libraries or
after sequence-based enrichment procedures (discussed
in the Supplemental Experimental Procedures).
The relative cloning frequencies of miRNAs represent
a measure of miRNA expression. We implemented three
distinct ways of visualizing miRNA expression patterns.
(1) We represent each mature miRNA sequence inde-
pendently. (2) Assuming that similar miRNAs regulate sim-
ilar targets, we defined ‘‘sequence groups’’ of mature
miRNAs based on sequence similarity (Table S16;
Figure S3). (3) We grouped miRNA precursors that either
share a mature form (multicopy miRNAs) or are clustered
in the genome in ‘‘precursor clusters’’ (Tables S17–S19).
Available cDNA and EST expression evidence supports
most of our spatially linked precursor clusters, and pair-
wise comparison of the relative expression of clustered
mature miRNAs across tissues yielded higher correlation
coefficients than for nonclustered miRNAs (r = 0.49 for
mouse and human versus r = 0.11 and 0.15 for mouse
and human, respectively; Tables S20–S22). We named
precursor clusters according to the name of the lowest
numbered cluster member and added in brackets the
number of members in the cluster (e.g., expression from
the hsa-mir-15a/mir-16-1 genes and hsa-mir-15b/mir-
16-2 genes was summarized in the precursor cluster-
hsa-mir-15a(4)); miRNA sequence families were named
with similar convention. For the comparison of miRNA
profiles and clustering of samples, we used a Bayesian
probability framework that takes into account the sam-
pling noise affecting the relative frequencies of miRNAs.
A web-accessible database (http://www.mirz.unibas.ch/
smiRNAdb) allows users to perform sequence searches
and to visualize and analyze the miRNA expression pro-
files across individual samples or groups of samples.
Technical and biological replicates indicated that
miRNA cloning frequencies are reproducible (Figure S3).
We then compared the cloning frequencies of five of our
samples with signal intensities from miRNA microarrays
using the same input total RNA (Figures S4 and S5) and
observed a strong and significant correlation of expres-
sion ranks within each sample. Furthermore, our cloning
profiles correlated with most liver and brain profiles re-
ported by many other laboratories (Figure S6). In order
to evaluate how miRNA cloning frequencies correlate
with the actual miRNA concentration across samples,
we determined the absolute amount of several miRNAs
in a subset of our samples by quantitative northern
blotting. We found a significant correlation between
miRNA clone frequencies and concentrations measured
by northern blotting (Figures S7–S11). To assess how
well cloning frequencies reflect relative concentrations
within a sample and to identify potential systematic biases
in our library preparation protocol, we prepared a pool of
816 synthetic 50 phosphorylated oligoribonucleotides
with known relative concentrations containing the pre-
dominantly cloned miRNA sequences. We sequenced
a total of 7498 miRNA clones from two independently pre-
pared libraries (Table S23). Although the miRNA clone
counts correlated significantly with their concentrationsin the pool, the correlation coefficient was rather low. To
a large extent, this is expected for the relatively small
sample sizes, as shown by resampling tests (Figure S12;
Supplemental Experimental Procedures). However, be-
cause the clone counts of the two libraries correlated bet-
ter with each other than two resampled samples did, we
conjectured that a systematic bias must also be present
in the cloning protocol. The most likely source of this
bias is the secondary structure of the different small
RNAs that affect the adaptor ligation efficiency. Such
a RNA self-structure-dependent bias would also explain
the robust correlation of miRNA profiles across samples
and to miRNA array platforms.
Sequence Variations in Mature miRNA Sequences
Approximately 20% of miRNA clone sequences in human,
mouse, and rat contained mismatches with respect to their
genomic locus that were caused by posttranscriptional
modification and/or PCR and sequencing errors. We iden-
tified sequence variations for 143 different human and 109
mouse miRNA genes above the sequencing error back-
ground (Figure 1; Tables S24 and S25). The frequency of
sequence alteration (Table S26) was dependent on the
specific nucleotide and its position within the miRNA and
was sometimes also tissue dependent (Tables S27 and
S28). The prevailing modifications were caused by A-to-I
editing (identified as A-to-G changes) and 30 terminal A
and U additions. The A-to-G transitions (Figure 1C) oc-
curred at 4-fold lower frequency in mouse than in human
(0.5% in mouse and 2.2% overall in human), in agreement
with recent reports of substantially higher A-to-I editing in
primates (Kim et al., 2004; Eisenberg et al., 2005).
Classifying miRNAs to Guide miRNA Functional
Analysis
The most important criteria for annotating a cloned
sequence as a miRNA are their characteristic length
(22 nucleotides) and a compact pre-miRNA fold-back
structure (Ambros et al., 2003). Furthermore, miRNAs gen-
erally adhere to additional properties including precise 50
end processing, asymmetric strand accumulation, and
sequence conservation. Surprisingly, not all miRNA se-
quences complied with these criteria when we examined
the large number of miRNA clones obtained in our study.
Therefore we subdivided miRNAs into four categories (Ta-
bles S29–S31, for details see Supplemental Experimental
Procedures). We termed the miRNAs in those categories
‘‘prototypical,’’ ‘‘repeat-clustered,’’ ‘‘repeat-derived,’’ and
‘‘unclassified’’ miRNAs.
miRNAs were considered prototypical if they met de-
fined criteria regarding their 50 end processing, lack of
repetitiveness, and cross-species conservation. More
than 97% of our miRNA clones originated from prototypi-
cal miRNA genes. Overall, 59% of all miRNA genes were
classified as prototypical.
Repeat-clustered and repeat-derived miRNAs originate
from highly repetitive genomic sequences, either clus-
tered or dispersed (Smalheiser and Torvik, 2005). InCell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc. 1403
Table 1. miRNAs Identified in This Study and Not Listed in miRBase (Release 9.1)
Human
miRNA Sequence
Clone
#
Mouse
miRNA Sequence
Clone
#
Rat
miRNA Sequence
Clone
#
miR-
872__FM
AAGGUUACUUG
UUAGUUCAGG
11 miR-872 AAGGUUACUUG
UUAGUUCAGG
394 miR-872 AAGGUUACUUG
UUAGUUCAGG
373
miR-879 AGAGGCUUAUA
GCUCUAAGCC
33 miR-879 AGAGGCUUAUA
GCUCUAAGCC
5
miR-8822 AGGAGAGAGUU
AGCGCAUUAGU
1 miR-882a6 AUGGGAAUGUU
AGAGCAUUAGC
0
miR-882b AUGGCAAUGUU
AGAGCAUUAGC
0
miR-874 CUGCCCUGGCC
CGAGGGACCGA
17 miR-874 CUGCCCUGGCC
CGAGGGACCGA
2 miR-874 CUGCCCUGGCC
CGAGGGACCGA
0
miR-877 GUAGAGGAGA
UGGCGCAGGG
40 miR-877 GUAGAGGAGA
UGGCGCAGGG
6 miR-877 GUAGAGGAGA
UGGCGCAGGG
2
miR-297c3 AUGUAUGUGUG
CAUGUACAUGU
16
j miR-743b4 GAAAGACAUCA
UGCUGAAUAGA
8 j miR-743b7 GAAAGACACCA
UACUGAAUAGA
0
j miR-883a UAACUGCAACA
GCUCUCAGUAU
6
j miR-883b UAACUGCAACA
UCUCUCAGUAU
1 j miR-883 UAACUGCAACA
UCUCUCAGUAU
0
j miR-880 UACUCCAUCCU
CUCUGAGUAGA
119 j miR-880 UACUCCAUUCA
UUCUGAGUAGA
3
j miR-878 GCAUGACACCA
CACUGGGUAGA
22 j miR-878 GCAUGACACCA
UACUGGGUAGA
1
j miR-874 AACUGUGUCUU
UUCUGAAUAGA
60 j miR-881 AACUGUGGCAU
UUCUGAAUAGA
0
miR-
871__FM
UAUUCAGAUUAG
UGCCAGUCAUG
2 j miR-871 UAUUCAGAUUAG
UGCCAGUCAUG
11 j miR-871 UAUUCAGAUUGG
UGCCGGUCACA
0
j miR-8901 UACUUGGAAAG
GCAUCAGUUG
10
j miR-888 UACUCAAAAAG
CUGUCAGUCA
16
j miR-465d UAUUUAGAAUG
GUACUGAUGUG
0
j miR-892b CACUGGCUCCU
UUCUGGGUAGA
14 j miR-465c UAUUUAGAAUG
GCGCUGAUCUG
42
j miR-891b UGCAACUUACC
UGAGUCAUUGA
4
j miR-891a UGCAACGAACC
UGAGCCACUGA
24
j miR-466f5 UACGUGUGUGU
GCAUGUGCAUG
7
j miR-466e GAUGUGUGUGU
ACAUGUACAUA
1.5
j miR-466b GAUGUGUGUGU
ACAUGUACAUG
7
j miR-466b8 UAUGUGUGUGU
GUAUGUCCAUG
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Table 1. Continued
Human
miRNA Sequence
Clone
#
Mouse
miRNA Sequence
Clone
#
Rat
miRNA Sequence
Clone
#
j miR-466c GAUGUGUGUGU
GCAUGUACAUA
11
j miR-466c UGUGAUGUGUG
CAUGUACAUG
2
j miR-467e AUAAGUGUGAG
CAUGUAUAUGU
125
j miR-466d UGUGUGUGCGU
ACAUGUACAUG
4
j miR-466g AUACAGACACA
UGCACACACA
2
j miR-466h UGUGUGCAUGU
GCUUGUGUGUA
4
miR-885 UCCAUUACACU
ACCCUGCCUCU
5
miR-887 GUGAACGGGCG
CCAUCCCGAGG
3
miR-886 CGCGGGUGCUU
ACUGACCCUU
16
The predominantly cloned sequence and orthologs are indicated. Bars beside the name indicate clustered miRNAs.
1 Part of the cluster-hsa-mir-888(6), epididymis-specific expression.
2 Part of the cluster-mmu-mir-134(33), enriched in embryonic tissue.
3 Part of the cluster-mmu-mir-297a-1(46).
4 Part of the cluster-mmu-mir-463(19), epididymis (testis) enriched expression.
5 Part of the cluster-mmu-mir-297a-3(43).
6 Part of the cluster-rno-mir-134(41).
7 Part of the cluster-rno-mir-463(12).
8 Part of the cluster-rno-mir-297c(4); Abbreviations are as follows: FM: ‘‘from mouse’’; the same miRNA sequence as in mouse was
cloned but could not be found in the current human assembly.human and mouse, we identified only a single repeat-clus-
ter. The human cluster contains 40 sequence-related pre-
cursors that are coexpressed in placenta (see also Bent-
wich et al., 2005), whereas the mouse cluster consists of
43 precursors preferentially expressed in neuronal tis-
sues. In contrast to the human repeat-clustered miRNAs,
the mouse repeat-clustered miRNAs had additional
matches to nearly 2000 dispersed regions in the mouse
genome, and we therefore called them also repeat-
derived. In contrast to prototypical miRNAs, precursors
of repeat-clustered miRNAs did not preserve the strand
asymmetry between sequence-related precursors. Fi-
nally, from the dispersed repeat miRNA category, we
identified 75 and 74 miRNA genes in human and mouse,
respectively. The overall cloning frequency of all repeat-
associated miRNA sequences was 2.6%, though the
number of genes in this category represented more than
23% of all miRNA genes.
The remaining 28% of miRNA genes were termed un-
classified, and their clone counts only amounted to
0.4% of all miRNA clones in our study. We found evidence
of expression for 42.3% of these genes, and their prod-
ucts showed irregularities in processing and/or unusualsequence variations including deletions and variation in
the seed sequence between human and rodent orthologs.
In order to assess if our classification scheme of
miRNAs has functional implications, we computed the
number of conserved 30 UTR sequence segments com-
plementary to position 1 to 8 (seed) of conserved miRNAs
(the ‘‘signal’’) and of shuffled sequences (the ‘‘noise’’;
Lewis et al., 2005). Prototypical miRNAs showed an en-
richment for putative target sites (average signal-to-noise
ratio = 3.2:1), consistent with previous analyses of smaller
sets of predominantly prototypical miRNAs (Lewis et al.,
2003, 2005; Stark et al., 2005). Repeat-derived miRNAs
showed an average ratio of 1.2:1, while unclassified
miRNAs had an average ratio of 1.0:1, suggesting that
nonprototypical miRNAs either have fewer conserved
mRNA targets and/or different requirements for mRNA
targeting.
Specificity of miRNA Expression in Human, Mouse,
and Rat Organs and Cell Types
Understanding cell-type specificity of miRNA expression
is an important step in elucidating miRNA function. We de-
fined this in terms of information content of the distributionCell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc. 1405
of the relative cloning frequencies in each individual tissue
type (see Experimental Procedures and Tables S32–S34).
The miRNA expression varied from highly specific to ubiq-
uitous and, for conserved miRNAs, was comparable be-
tween rodents and human. Surprisingly, very few miRNAs
were exclusively found in individual tissues or cell types,
and only a third of the analyzed miRNAs were expressed
with a higher degree of tissue specificity (Figure 2A).
When we examined the overall miRNA cloning frequency,
we noticed that several abundant miRNAs were ubiqui-
tously expressed, even in embryonic derived cell lines
and tissues (Figure 2B). Most notably, miR-16, which is
encoded by the mir-15a/mir16-1 and the mir-15b/mir16-2
polycistrons, was always among the most abundantly
cloned miRNAs in each of the over 250 samples analyzed.
miR-21 was detected in the majority of samples, but, in
contrast to miR-16, its relative cloning frequency varied
Figure 1. Nucleotide 30 Additions and Editing Events in
Mature miRNA Sequences
Examples for 30 A additions (A), U additions (B), and A-to-G nucleotide
exchanges due to possible deamination events (C) are given. Nucleo-
tides of sequenced miRNAs that do not match their genomic sequence
are colored. The black bar underneath each sequence logo indicates
the predominantly cloned sequence. A list of all modifications and their
occurrence in the different libraries is given in Tables S24 and S25.1406 Cell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc.greatly and was higher in tumor samples and cell lines
compared to normal tissues.
The expression patterns of miRNAs were recently ex-
amined by in situ hybridization analysis during develop-
ment of zebrafish and mouse, and in human brain samples
(Wienholds et al., 2005; Kloosterman et al., 2006a, 2006b;
Nelson et al., 2006). The derived expression patterns
largely overlap with our cloning data for miRNA precursor
clusters analyzed in both studies (Table S32). However,
for some miRNAs (e.g., mir-200a(3), mir-203(1), hsa-mir-
141(2)), we find enriched expression in other tissues be-
sides those noted in zebrafish.
Analysis of miRNA Expression in Normal
and Malignant Cells of the Hematopoietic System
Distinct cell populations of the hematopoietic system
accumulate in acute leukemia and lymphoma making it
an interesting model system for studying basic mecha-
nisms of stem cell maintenance, differentiation, and malig-
nant transformation. Regulation of a subset of miRNAs
during hematopoiesis has been studied in mouse and hu-
man by microarray analysis and northern blotting (recently
reviewed by Kluiver et al., 2006), but a comprehensive
analysis of the human hematopoietic system and its asso-
ciated diseases is lacking. We prepared 98 different small
RNA libraries from the human hematopoietic system in-
cluding sorted cell populations from healthy donors,
whole bone marrow, and tumor biopsies collected from
patients with hematopoietic malignancies and various
cell lines (Figure 3). Comparison of miRNA expression in
the hematopoietic system to all other organ systems
examined in this study indicates that only five miRNAs
are highly specific for hematopoietic cells: miR-142,
miR-144, miR-150, miR-155, and miR-223.
Hierarchical clustering (see Supplemental Experimental
Procedures) showed that lymphoid cells cluster separately
from stem cells and from cells derived from the myeloid lin-
eage (Figure 3A). Patient samples and cell lines of the B-
lymphoid lineage clustered in distinct subgroups mostly
consistent with the diagnosis (Figure 3B). This was caused
by variation in the expression of a small number of miRNAs
including themir-181a-1(4) cluster, which was absent from
B-cell chronic lymphocytic leukemia (B-CLL) patient sam-
ples and mature B-cells, and miR-126, which was strongly
expressed in precursor B-cell acute lymphoblastic leuke-
mia (pre-B-ALL) samples, bone marrow from patients in re-
mission, and most germinal center-derived lymphoma
(5.8% average relative cloning frequency) but not in the
germinal center-derived Burkitt’s lymphoma and several
lymphoma cell lines. In Burkitt’s and diffuse large B-cell
lymphoma (DLBCL) miR-150 expression was reduced
about 20-fold in comparison to other closely related germi-
nal center malignancies. In the T-lymphoid lineage the
miRNA expression profiles of sorted different mature T
cell types were similar and clustered together (Figure 3C).
In contrast to patient samples for pre-B-ALL, the miRNA
profiles from bone marrow samples of T-ALL patients be-
fore and after remission were not clearly distinct, whereas
Figure 2. Tissue Specificity of miRNA
Expression
(A) The 51 most specific miRNA precursor clus-
ters for human and mouse are depicted. The
total height of each bar represents the informa-
tion content reflecting tissue specificity, while
the relative heights for each of the tissues are
proportional to the clones of a miRNA precur-
sor cluster in a given tissue type relative to all
tissue types. The enrichment of miR-124 in
the endocrine tissue in mouse is due to high ex-
pression of this miRNA in the MIN-6 b cell line,
but miR-124 is not expressed in primary b cells
residing in mouse or human islets.
(B) The 26 most expressed miRNA precursor
clusters for human and mouse are depicted.
The mean clone count for each tissue type
(striped bars) and the tissue specificity (white
bars) are indicated. The most abundant miRNA
clusters are ubiquitously expressed and show
little tissue specificity.in the myeloid lineage disease bone marrow samples clus-
tered separately from samples of patients in remission
(Figure 3D). We did not find any striking differences in the
miRNA expression profile of cell lines derived from differ-
ent myeloid sublineages, except for the induction of ex-
pression of the granulocyte/monocyte-specific miR-223.
miRNA Profiles of Tissues and Cells of the Nervous
System in Human and Rodents
To assess whether differential miRNA expression in the
nervous system contributes to its complex cell-type com-position, we investigated expression of miRNAs in differ-
ent brain regions in human, mouse, and rat (Figures 4A,
4B, and 4C, respectively). miR-9, miR-124, miR-128a,
and miR-128b were highly and specifically expressed in
all brain regions, (38.6% relative cloning frequency) ex-
cept for pituitary gland, that showed abundant expression
of miR-7, miR-375, and the clusters of mir-141(2) and mir-
200a(3) (19.8%; Figure 4A). Cluster analysis based on the
expression of orthologous miRNAs separates the human
adult brain regions from those of adult rat brain, with the
exception of the hippocampus region.Cell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc. 1407
Figure 3. miRNA Expression in Hemato-
poietic Lineage Differentiation
miRNA precursor clusters with at least 5% rel-
ative cloning frequency in at least one of the
samples are depicted individually in a color
code. All other miRNAs and viral miRNAs
were pooled and are displayed together. Unde-
tected miRNAs are displayed in black. Hema-
topoietic-specific miRNA clusters are marked
by black dots. B-, T-, and dendritic cell (DC)
samples were combined, and their composite
profiles are shown in (A), while (B), (C), and
(D), respectively, show the individual samples.
The lineage is indicated above each Figure. Dif-
ferent disease entities and normal cells are indi-
cated with color bars. Patient-derived samples
are labeled with the disease name and patient
number, while for cell lines the respective
names are given. The FAB classification is
given for the AML samples, and the progenitor
cells are indicated. Abbreviations are as fol-
lows: LMPP, lymphoid primed multipotent pro-
genitor; CLP, common lymphoid progenitor;
CMP, common myeloid progenitor; GMP,
granulocyte/macrophage progenitor; MkEP,
megakaryocyte/erythrocyte progenitor; BM re-
mission, bone marrow in remission; DLBCL,
diffuse large B cell lymphoma; MZ, marginal
zone; MC, mantle cell; FL, follicular lymphoma;
BL, Burkitt’s lymphoma; PC, plasmocytoma;
and HL, Hodgkin lymphoma.To assess whether miRNA expression changes during
embryonic development of the brain, we investigated
miRNA profiles of embryonic and adult striatum and cor-
tex in rat (Figure 4C). Adult and embryonic brain tissues
clustered separately due to expression of the mir-29a(4)
cluster, which is absent in the embryonic tissues but is
expressed at high frequency in the adult cortex (5.6%)
and adult striatum (8.8%).
Analysis of miRNA profiles of cell lines and patient
material derived from the central or the sympathetic ner-
vous system revealed expression differences according
to the glial or neuronal cellular origin of the tumor. The
most striking difference was the near absence of the neu-
ron-specific miR-124 in the glial tumors and its presence
in neuroblastoma derived from sympathetic neurons.
Consistent with previous reports (Chan et al., 2005),
miR-21 was 5- to 32-fold upregulated in all glial-derived
tumors or cell lines compared to midbrain (0.3%). The
miRNA profiles of mouse neuroblastoma were consistent
with their human counterpart, except for the presence of
the mouse-specific cluster of mir-297a-1(46) (12.3% aver-
age cloning frequency), which was not expressed in1408 Cell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc.normal mouse brain. Unexpectedly, the neuroblastoma
cell line B35 from rat did not express miR-124, and its
miRNA profile was very similar to the rat glioblastoma
cell line C6.
Finally, in order to evaluate the role of Fragile X mental
retardation protein (FMRP), which was shown to interact
with DICER and AGO protein in the miRNA pathway
(Caudy et al., 2002; Jin et al., 2004; Plante et al., 2006),
the miRNA profile of the whole brain of 4-day-old FMRP
knockout mice and homozygous wild-type littermate
were compared, but no differences in miRNA expression
were observed (Figure 4B). FMRP apparently does not af-
fect miRNA maturation or miRNP assembly and may at
most play a role in downstream mRNA target recognition.
miRNA Expression Changes in Cell Differentiation
Experiments
As model systems for neuronal differentiation, we treated
neuroblastoma (B35, SH-SY5Y, NG, N1E, and N2A) and
embryonic carcinoma (NTera2) cell lines with dibutyryl cy-
clic AMP (cAMP), retinoic acid (RA), and FBS-deficient
media until we observed the characteristic morphologic
Figure 4. miRNA Expression in the Ner-
vous System
Expression profiles of miRNA precursor clus-
ters with at least 5% relative expression in
one of the samples as well as the neuronal-spe-
cific miRNA clusters (marked with black dot)
are depicted individually for human (A), mouse
(B), and rat (C) brain sections, brain tumor sam-
ples (FC0020688, WL210995, DD040800), and
cell lines as indicated (color code of expression
values see Figure 3). The open circles indicate
miRNAs enriched in endocrine tissue including
the pituitary gland. All panels show orthologous
miRNA precursor clusters (if present). Abbrevi-
ations are as follows: dcAMP, dibutyryl cAMP;
FBS, fetal bovine serum; TPA, transphorbol
ester; RA, retinoic acid; and orth indicates
that the hsa-mir-470 cluster is orthologous to
the rodent mir-463 clusters.changes indicative of neuronal differentiation (Figure 5A).
The most significant change in miRNA expression was
observed after dibutyryl cAMP treatment of the rodent
neuroblastoma cell line B35, when the frequency of the
rat mir-16 cluster (mir-15b(2)) drops from 13.1% to
1.2%. The behavior of the human Ntera2 embryonic carci-
noma cell line was unique in that RA treatment turned on
the expression of the mir-21 (8.9%), mir-141(2) (9.6%),
and mir-371(46) (9.4%) clusters, while the neuronal miR-
124 was only detected at low levels (1.4%) and was not
induced.
To assess miRNA involvement in osteoblast differentia-
tion, we differentiated unrestricted somatic stem cells
(USSCs) obtained from umbilical cord blood (Koegler
et al., 2004) as well as the renal carcinoma cell line (DH-
1) for 1, 3, and 7 days and for 3 and 6 days, respectively
(Figure 5B). The expression of the hematopoietic-specific
miR-142 decreased from 5.0% to 0.3% after 7 days
in USSCs, while the let-7 clusters (mir-98(13)) increased
2- to 3-fold after 7 days in USSCs and after 3 days in the
DH-1 cell line to 26.3% and 33%, respectively. In the latter
there was a significant degree of apoptosis following dif-
ferentiation, and the trend observed after day 3 was not
followed beyond day 6.We also examined a restricted thyroid cell line FRTL-5
that depends on the presence of thyroid-stimulating hor-
mone (TSH) or on the induction of a stable, ectopic tamox-
ifen-regulated RAS oncogene (De Vita et al., 2005). Ras
induction led to dedifferentiation, to TSH-independent
proliferation of the thyroid cells, and to upregulation of
miR-21 after 2 and 7 days from 0.3% to 4% and 11% total
miRNA content, respectively (Figure 5C).
Interferon treatment was shown to induce hundreds of
interferon-regulated genes (Stark et al., 1998; van Boxel-
Dezaire et al., 2006). Treatment of human A549 and
HeLa S3 cell lines with interferon a, b, or g, however, did
not cause any substantial changes in miRNA profiles,
while we confirmed by qRT/PCR the strong upregulation
of interferon-induced OAS1 (50-fold) and IRF1 (200-fold)
mRNAs (Figure S13).
DISCUSSION
The estimated number of miRNA genes in mammalian ge-
nomes has been steadily increasing, reaching currently
tens of thousands (Berezikov et al., 2005; Xie et al.,
2005; Rigoutsos et al., 2006). These numbers appear to
be supported, at least at first glance, by studies usingCell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc. 1409
Figure 5. miRNA Expression in Cell Differentiation Experiments
Cell lines were treated and differentiated into neurons (A) and osteoblasts (B).
(C) A thyroid-stimulating hormone (TSH)-dependent rat cell line FRTL5 was dedifferentiated by induction of a chimeric RAS protein. Expression pro-
files for orthologous miRNA precursor clusters with 5% or more relative cloning frequency in at least one sample are depicted in a color-coded manner
(see Figure 3 for details). Abbreviations: dcAMP, dibutyryl cAMP; FBS, fetal bovine serum; TPA, transphorbol ester; RA, retinoic acid; USSC, human
unrestricted somatic stem cell; and orth indicates that the hsa-mir-470 cluster is orthologous to the rodent mir-463 clusters.deep-sequencing technologies (Berezikov et al., 2006a,
2006b; Cummins et al., 2006; Kloosterman et al., 2006a)
or specialized small RNA isolation and cloning procedures
(Bentwich et al., 2005; Takada et al., 2006). Furthermore,
the cell-type-specific expression of some miRNAs sug-
gested that many more miRNAs could surface if only a suf-
ficiently large number of cell types or tissues were studied.
In order to derive a miRNA gene expression atlas that sets
into perspective the number and functional relevance of
miRNA genes, we have taken the approach of cloning
and sequencing over 250 small RNA libraries from differ-
ent cell types and tissues, with 1,000 miRNA clones
per library. We provide the data as well as analysis tools
on a web-accessible interface. We believe that these will
be instrumental in guiding the rapidly developing field of
miRNA biology.
We characterized the profiles of complex tissues,
sorted cells, and individual cell lines and found on average
70 miRNA genes expressed per sample. Only a small1410 Cell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc.fraction of these appeared to be regulated in cell differen-
tiation experiments. We did not find evidence for substan-
tial induction of many of the new candidate miRNAs iden-
tified as rare cloning events in deep-sequencing surveys
despite the analysis of over 330,000 small RNA clones
obtained from 256 small RNA libraries from different cell
types and tissues.
The large overall number of miRNA clones obtained
from human, mouse, and rat samples allowed us to ana-
lyze the processing patterns for each miRNA. We found
that at least 40% of miRNA sequences deposited in
miRBase (v8.2) do not represent the predominantly cloned
sequence either because of differences in 30 or 50 end
processing or because of miRNA/miRNA* strand selec-
tion. In addition, we analyzed a large number of features
of miRNA genes, including sequence conservation and
their relationship to genomic repeats. This analysis led
us to conclude that more than 97% of all miRNA clones
originated from less than 300 miRNA genes per
species—genes that satisfied a series of general proper-
ties expected to be met by prototypical miRNAs (Ambros
et al., 2003; Bartel, 2004). Surprisingly, only 17% of
all miRNA sequences identified by a recent deep-
sequencing study (Cummins et al., 2006) were prototypi-
cal. The remaining miRNAs, though clearly originating
from hairpin precursors, showed unusual maturation or
sequence conservation patterns. With rare exceptions,
these miRNAs were also found at low levels and/or did
not exhibit cell-type-specific expression. For many more
recently reported miRNA candidates, we do not have
cloning evidence. We speculate that these small RNAs
originate from dsRNA structures that only accidentally
enter the RNAi pathway, such as fold-back elements con-
trolled by dsRNA deaminases or the binding sites of RNAi-
unrelated dsRNA-binding proteins.
Several different methods have been used in the past
years for miRNA expression profiling (reviewed in Aravin
and Tuschl, 2005). Unfortunately, there was no universal
or synthetic miRNA reference standard available to assess
the correlation of signal intensities with the absolute
miRNA concentration of the sample. We therefore com-
pared some miRNA profiles from small RNA cloning to
those obtained from our newly developed miRNA array
platform as well as to absolute amounts determined by
quantitative northern blotting of a small subset of miRNAs.
For the new miRNA array platform, we synthesized a uni-
versal miRNA standard from which we also prepared small
RNA libraries that we cloned and sequenced. Relative
clone frequencies for a given miRNA correlated signifi-
cantly with quantitative northern blotting results for these
miRNAs across samples, but we also detected a system-
atic bias in our library preparation method. When we com-
pared our brain and liver cloning profiles with those
obtained by various other methods in the literature, we
generally observed a good correlation, suggesting that
the discrepancies between actual miRNA concentrations
and those measured by various high-throughput methods
are intrinsic to the miRNA sequence and their specific
secondary self-structure.
From our miRNA expression atlas we computed the
tissue and cell-type specificity of miRNA expression. Our
data are in good agreement with previously published in
situ analysis in mouse (Kloosterman et al., 2006b). A
more detailed comparison of miRNA profiles originating
from similar tissues showed differences not only in cell-
type-specific miRNAs, but also in ubiquitously expressed
miRNAs. The relative expression of these ubiquitous
miRNAs in different cell types is difficult to quantify by in
situ analysis.
We included in our study a large number of cell lines and
primary patient material from many cancers to define
starting points for higher-throughput approaches like
miRNA microarrays. Understanding deregulation of
miRNA expression, and making decisions on the selection
of candidates to examine in a certain disease context, is
much more informative in the context of a large expression
database. We have provided a thorough overview ofmiRNA profiles in diverse leukemia, lymphoma, and brain
tumors, and we have defined a conservative set of rele-
vant miRNA cistrons mediating miRNA regulation in these
diseases.
Although we explicitly searched in all of our libraries for
possible mutations in miRNAs that might impair or change
function, we found only low-abundant variations that
could be explained by RNA-editing events such as deam-
ination, or 30 end processing of stable intermediates and
miRNAs by transferases and poly(A) and poly(U) polymer-
ases. The frequency of these modifications was low for the
vast majority of miRNAs, suggesting that these modifica-
tions play a limited role in miRNA function.
In summary, we established a first mammalian miRNA
gene atlas based on sequencing from small RNA libraries.
We included miRNA profiles from a large collection of
mammalian cell and tissue samples, and we developed
tools for miRNA profile analysis and presentation, which
will assist future research on miRNA function and its impli-
cation in disease. This atlas will continue to grow in utility
as additional libraries are cloned and sequenced.
EXPERIMENTAL PROCEDURES
Details about the procedures and protocols used in our studies are
given in the Supplemental Experimental Procedures. Here we summa-
rize briefly the main features of our methods.
Cell Lines and Tissues
Cell lines were cultured according to guidelines provided by ATCC
(www.atcc.org) and DSMZ (www.dsmz.de) and incubated at 37C in
5% CO2. Cells were differentiated as published elsewhere with details
and references given in the Supplemental Experimental Procedures.
Human tissue samples or RNA isolated thereof was obtained follow-
ing the written consent of the person and/or legal guardian (where
applicable), and the identity was obscured for reasons of privacy. Nor-
mal tissue was dissected postmortem. Human pancreatic islet tissue
was obtained from pancreatic islet donors for transplantation. Sorted
cells were obtained using magnetic DynaBeads (Dynal) according to
the manufacturer’s instructions from peripheral blood of healthy
donors that were stimulated with G-CSF. Brain tumor samples
hsa_FC020688, hsa_WL210995, and hsa_DD040800 were obtained
at diagnosis at the University Hospital of Giessen, Germany, and
were flash frozen in liquid nitrogen. The diagnosis of those was con-
firmed histologically. ALL, acute myeloblastic leukemia (AML), and
Burkitt’s lymphoma patient samples were obtained from bone marrow
aspirate at indicated time points, while CLL patient samples were
isolated from peripheral blood. Marginal zone lymphoma, follicular
lymphoma, and mantle cell lymphoma samples were obtained at diag-
nosis by tumor biopsy.
Total RNA Isolation, Small RNA Library Preparation,
Sequencing, and Sequence Annotation
Total RNA isolation and small RNA cloning were performed as
described previously (Pfeffer et al., 2003). Most samples were cloned
using preadenylated 30 adaptor oligonucleotides and the T4 RNA
ligase Rnl2(1–249) as described (Pfeffer et al., 2005). The annotation
procedure is outlined in Figure S1.
Construction of miRNA Precursor Clusters
Previous studies indicate that miRNAs that are closely spaced in the
genome are coexpressed, presumably due to being part of the same
transcription unit (Lee et al., 2004; Baskerville and Bartel, 2005). WeCell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc. 1411
have therefore defined clusters of potentially coexpressed precursors
based on the relative genomic distance of the precursors or their shar-
ing of a mature form.
Construction of miRNA Sequence Groups
Since miRNAs that are highly similar in sequence are likely to have
similar functions, we grouped miRNAs based on their similarity over
their entire length and not only based on the sequence identity of the
50 end of the miRNA (‘‘seed’’ or ‘‘nucleus’’).
Construction of the Orthology Table
We identified orthologous miRNA genes by mapping all human/
mouse/rat precursors to the three genomes and using the pairwise
genome alignments provided by the UCSC Genome Informatics group
(http://genome.cse.ucsc.edu) and the synteny information from the
published synteny maps (Murphy et al., 2005).
Comparing miRNA Expression between Samples
miRNA samples were compared in a Bayesian framework. The dis-
tance between two samples was computed as a function of the relative
ratio of likelihoods of two models, with one assuming that the relative
cloning frequency of each of the miRNAs was the same and the other
assuming that they are different between the two samples.
Hierarchical Clustering of Samples
We clustered samples hierarchically, using the distance measure de-
fined above. At every step during the clustering procedure, we com-
puted the number of miRNAs of a given type in the cluster as the
sum of the counts for that miRNA type in all the samples in the cluster.
We then grouped the two clusters whose distance is minimal among all
pairs of clusters.
Comparative Analysis of Expression of miRNAs from the Same
and from Different Precursor Clusters
All mature miRNAs for which we had at least five copies in at least ten
samples were used to investigate the correlation in expression of
miRNAs that are and those that are not closely spaced in the genome.
As a measure of correlation we used the Pearson correlation coeffi-
cient between the frequencies of any two miRNAs across tissues.
Analysis of miRNA Tissue Specificity
To quantify the specificity of the expression of mature miRNAs or
miRNA precursor clusters in the various tissue types and samples,
we first used the hierarchical tissue classification scheme to determine
the clone count of each miRNA or miRNA precursor cluster for each
tissue class. We then normalized the miRNA counts within each
sample and calculated a ‘‘normalized tissue enrichment’’ for each
miRNA as the ratio of the normalized clone count for one tissue type
relative to the total clone count. Finally, we calculated the information
content of the ‘‘normalized tissue enrichment’’ distribution across
tissue classes.
Sequence Modification Analysis
To identify sequence changes of mature miRNA sequences relative to
their genomic sequence we first built a position-independent back-
ground model of all sequence changes (Figure S14) and then reported
sequence changes that were significantly above the background in
a chi-squared analysis. Those sequence changes with at least two
observations at the same position in at least one library were collected
for each individual sequence change (Tables S24 and S25) and
summarized by position relative to the mature form for all sequence
changes (Table S26).
The tissue specificity or enrichment of the observed modifications
was calculated in a manner analogous to the tissue specificity of
miRNA expression described above. The computed information
scores for each modification are given in Tables S27 and S28, and1412 Cell 129, 1401–1414, June 29, 2007 ª2007 Elsevier Inc.modifications that occurred highly tissue specifically are indicated in
the modification Table (Tables S24 and S25).
miRNA Microarray Design and Hybridization
miRNA microarrays were designed as deoxyoligonucleotide arrays
(Miltenyi Biotech) and hybridized using standard conditions. Samples
and a synthetic pool of 816 oligoribonucleotides were separately
fluorescently labeled using miRCURY LNA microRNA Array labeling
kit (Exiqon). The obtained data were submitted to GEO (accession
number: GPL4867).
Supplemental Data
Supplemental Data include Experimental Procedures and 37 tables
and can be found with this article online at http://www.cell.com/cgi/
content/full/129/7/1401/DC1/.
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